Journal of Liver Cancer

Kyu Sung Rim

2 Articles

A Case of Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Tae Young Yang, Suk Pyo Shin, Joo Ho Lee, Yun Bin Lee, Hana Park, Seong Gyu Hwang, Kyu Sung Rim; J Liver Cancer. 2015;15(1):52-56. Published online March 31, 2015; DOI: https://doi.org/10.17998/jlc.15.1.52

Abstract PDF: Patients with advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) have an extremely poor prognosis. Although the Barcelona Clinic Liver Cancer guideline recommends sorafenib in advanced HCC with PVT, which has provided survival benefits of 2 or 3 months compared to the placebo group, many liver cancer centers in Asia still select multimodality approaches including transarterial chemoembolization, radiofrequency ablation, radiation therapy (RT) as well as systemic/intra-arterial chemotherapy. Recently advanced RT technologies have shown potential to improve survival without severe radiationrelated toxicity. For locally advanced HCC patients with PVT, concurrent chemoradiotherapy (CCRT) has been applied as a loco-regional treatment and provides potential cures. We herein report our recent experience of a patient accompanying large HCC with PVT who successfully undergone CCRT followed by hepatic arterial infusion chemotherapy.

A long-term survival case of advanced hepatocellular carcinoma with portal vein thrombosis successfully treated with multimodal treatments: Ju Hyun Choi, Han Eul Song, Chang Il Kwon, Kwang Hyun Ko, Sung Pyo Hong, Seong Gyu Hwang, Pil Won Park, Kyu Sung Rim, Man Deuk Kim, Sung Won Kwon; Journal of the Korean Liver Cancer Study Group. 2007;7(1):66-70. Published online June 30, 2007

Abstract PDF: We reported a 52-year-old women with hepatocellular carcinoma (HCC) of 10 cm in diameter involving entire right lobe with advanced tumor thrombosis in the both branches and main trunk of portal vein. She was treated with multimodal treatments resulting in a long-term survival of more than 5 years. At first, she was treated with hepatic arterial chemotherapy (HAC) using cisplatin and 5-FU for 5 cycles and radiation therapy in September 2002. The tumor size decreased and the main and left portal vein thrombosis was disappeared. Although, she had been treated with the 3th radiofrequency ablation (RFA) and the 3th transarterial chemoembolization (TACE) three times for the treatment of main tumor, follow-up CT scan still showed marginal viable tumor at the segment 5. Therefore, she was underwent right lobectomy of the liver and splenectomy. Further TACE was performed once for the small remnant tumor around inferior vena cava at the postoperative 4 months. Finally, she has been survived for over 5 years from the initial treatment and 23 months after operation without evidence of recurrence. We suggest that the long-term survival was achieved in this patient through appropriate treatment selections at the right time, such as HAC, RFA, TACE, hepatic resection and external radiotherapy based on changes in diagnostic imaging and tumor markers.